Randomized trial · people
CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, more people on CagriSema reached set BMI and waist-to-height goals than on semaglutide, cagrilintide alone or placebo, and those goals may be a useful way to track progress beyond the number on the scale.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2026
- Journal
- Diabetes Obes Metab
What they tested
The team asked whether body-size targets, BMI and waist-to-height ratio, add useful information beyond percentage weight loss when judging obesity treatment.
How the study was done
A secondary, post hoc look at REDEFINE 1, a 68-week phase 3a randomized trial in adults without diabetes who had a BMI of 30 kg/m2 or more, or 27 kg/m2 or more plus at least 1 obesity-related health problem. Once a week, people received the CagriSema combination (2.4 mg of each drug), semaglutide alone at 2.4 mg, cagrilintide alone at 2.4 mg, or placebo (a dummy treatment), each alongside lifestyle changes.

Model. Individual results vary.
What they found
At week 68, the share of people who reached both a BMI under 27 kg/m2 and a waist-to-height ratio (WHtR) under 0.53 was 30.3% with CagriSema, 19.1% with semaglutide, 9.0% with cagrilintide alone and 3.3% with placebo. BMI and WHtR worked about equally well as markers for reaching or keeping healthy levels in four heart and metabolic measures: blood sugar, blood pressure, triglycerides (a blood fat) and HDL cholesterol. When stricter cutoffs were used, the body-size targets tracked these outcomes better than percentage weight loss did.
What it doesn’t show
This was a post hoc analysis, meaning the questions were asked after the trial was done, so it shows links rather than proof that hitting a target causes better health. It only included adults without diabetes.
The paper
Busetto et al. Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. Diabetes Obes Metab. 2026.
The compounds
More studies on Cagrilintide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3Randomized trial · people · 2026
- Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1Randomized trial · people · 2025
- CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2Randomized trial · people · 2025
- Cagrilintide with semaglutide: 15.6% weight loss in type 2 diabetesRandomized trial · people · 2023
- Cagrilintide with semaglutide: 17.1% weight loss at 2.4 mg, week 20Randomized trial · people · 2021
- Every study on Cagrilintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.